Sponsors

Company Profile

LigoCyte Pharmaceuticals, Inc.

Antibodies

2155 Analysis Drive
Bozeman, MT 59718
USA
www.ligocyte.com 		Incorporated in 1998
49 Employees 		Privately Held

This Year's Highlights

  • Norovirus vaccines - tox studies underway. IND to be completed 1Q07, moving LigoCyte from a pre-clinical company into the clinical phase of development.
  • Four humanized anti-CD62 monoclonal antibody candidates successfully developed for COPD indication.
  • Significant NIH and DoD funding in place, revenue increased an average of 40%/year over past five years.

Anticipated Highlights

  • We expect to file Norovirus IND in 1Q07 and initiate Phase I trial in 2Q07.
  • We are well positioned to receive a clinical development contract for a third generation anthrax vaccine.
  • We expect to partner with other bio tech companies to further develop our monoclonal antibodies.

Corporate Mission

LigoCyte is a biopharmaceutical company focused on the development of vaccines and therapeutic drugs for preventing or treating diseases in specialty markets. Our mission is to apply our expertise in mucosal immunology to drug development for respiratory and gastrointestinal indications.